

# CITATION REPORT

List of articles citing

**Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers**

**DOI: 10.1007/s00262-006-0266-z**

**Cancer Immunology, Immunotherapy, 2007, 56, 1173-82.**

**Source:** <https://exaly.com/paper-pdf/43078232/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
389	The B7 family and cancer therapy: costimulation and coinhibition. <b>2007</b> , 13, 5271-9		277
388	Immunosuppressive mechanisms in human tumors: why we still cannot cure cancer. <b>2008</b> , 116, 7-14		53
387	PD-1 and its ligands in tolerance and immunity. <b>2008</b> , 26, 677-704		3557
386	Inhibitory B7-family molecules in the tumour microenvironment. <b>2008</b> , 8, 467-77		1165
385	The immunomodulatory glycan LNFPIII initiates alternative activation of murine macrophages in vivo. <b>2008</b> , 125, 111-21		67
384	The complex role of B7 molecules in tumor immunology. <b>2008</b> , 14, 550-9		71
383	Prowling wolves in sheep's clothing: the search for tumor stem cells. <b>2008</b> , 389, 799-811		9
382	T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival. <b>2008</b> , 14, 4800-8		204
381	The use of the inhibitory receptors for modulating the immune responses. <b>2008</b> , 14, 2643-50		17
380	Inhibitors of B7-CD28 costimulation in urologic malignancies. <b>2009</b> , 1, 129-39		9
379	Expression of the costimulatory molecule B7-H3 is associated with prolonged survival in human pancreatic cancer. <b>2009</b> , 9, 463		108
378	Interaction of B7-H1 on intrahepatic cholangiocarcinoma cells with PD-1 on tumor-infiltrating T cells as a mechanism of immune evasion. <b>2009</b> , 100, 500-4		87
377	PD-1/PD-L1 expression in human T-cell leukemia virus type 1 carriers and adult T-cell leukemia/lymphoma patients. <b>2009</b> , 23, 375-82		142
376	Negative regulators of T-cell activation: potential targets for therapeutic intervention in cancer, autoimmune disease, and persistent infections. <b>2009</b> , 229, 67-87		126
375	PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. <b>2009</b> , 206, 3015-29		1384
374	Cancer Epidemiology. <i>Methods in Molecular Biology</i> , <b>2009</b> ,	1.4	6
373	Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy. <b>2010</b> , 33, 225-35		148

372	Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade. <b>2010</b> , 37, 430-9		230
371	Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. <b>2010</b> , 37, 508-16		220
370	The emergence of immunomodulation: combinatorial immunochemotherapy opportunities for the next decade. <b>2010</b> , 116, 222-33		28
369	Unexpected acceleration of type 1 diabetes by transgenic expression of B7-H1 in NOD mouse peri-islet glia. <b>2010</b> , 59, 2588-96		15
368	Immunobiology of cancer therapies targeting CD137 and B7-H1/PD-1 cosignal pathways. <b>2011</b> , 344, 245-67		36
367	Role of PD-1 in regulating T-cell immunity. <b>2011</b> , 350, 17-37		198
366	Cancer Immunology and Immunotherapy. <b>2011</b> ,		1
365	Immunotherapy for renal cell carcinoma. <b>2011</b> , 25, 793-812		22
364	PD-1 and autoimmunity. <b>2011</b> , 31, 265-95		18
363	Immunostaining of PD-1/PD-Ls in liver tissues of patients with hepatitis and hepatocellular carcinoma. <b>2011</b> , 17, 3322-9		104
362	Early T cell signalling is reversibly altered in PD-1+ T lymphocytes infiltrating human tumors. <i>PLoS ONE</i> , <b>2011</b> , 6, e17621	3-7	71
361	Upregulation of circulating PD-L1/PD-1 is associated with poor post-cryoablation prognosis in patients with HBV-related hepatocellular carcinoma. <i>PLoS ONE</i> , <b>2011</b> , 6, e23621	3-7	123
360	Beyond cancer vaccines: a reason for future optimism with immunomodulatory therapy. <i>Cancer Journal (Sudbury, Mass)</i> , <b>2011</b> , 17, 372-8	2.2	24
359	Paclitaxel induced B7-H1 expression in cancer cells via the MAPK pathway. <b>2011</b> , 23, 295-9		33
358	Expression of B7-H3 in hypopharyngeal squamous cell carcinoma as a predictive indicator for tumor metastasis and prognosis. <b>2011</b> , 38, 1219-26		40
357	Role of PD-L1 and PD-L2 in allergic diseases and asthma. <b>2011</b> , 66, 155-62		83
356	Relationship between the expressions of PD-L1 and tumor-infiltrating lymphocytes in oral squamous cell carcinoma. <b>2011</b> , 47, 1148-53		160
355	Clinical significance of the costimulatory molecule B7-H1 in Barrett carcinoma. <b>2011</b> , 91, 1025-31		41

354	Immunologic biomarkers as correlates of clinical response to cancer immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , <b>2011</b> , 60, 433-42	7.4	103
353	Immunosuppressive tumor microenvironment in cervical cancer patients. <b>2011</b> , 4, 361-75		77
352	PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients. <b>2011</b> , 128, 887-96		299
351	Tumor-infiltrating programmed death receptor-1+ dendritic cells mediate immune suppression in ovarian cancer. <b>2011</b> , 186, 6905-13		179
350	Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells. <b>2011</b> , 17, 4232-44		262
349	Tumor evasion from T cell surveillance. <b>2011</b> , 2011, 918471		105
348	Targeting costimulatory molecules to improve antitumor immunity. <b>2012</b> , 2012, 926321		53
347	Clinical Significance of Programmed Death-1 Ligand-1 Expression in Patients with Non-Small Cell Lung Cancer: A 5-year-follow-up Study. <b>2012</b> , 98, 751-755		134
346	Molecular pathways: next-generation immunotherapy--inhibiting programmed death-ligand 1 and programmed death-1. <b>2012</b> , 18, 6580-7		415
345	The expression, function, and clinical relevance of B7 family members in cancer. <i>Cancer Immunology, Immunotherapy</i> , <b>2012</b> , 61, 1327-41	7.4	62
344	Plasmacytoid dendritic cells are inefficient in activation of human regulatory T cells. <i>PLoS ONE</i> , <b>2012</b> , 7, e44056	3.7	7
343	Targeting Immune Checkpoints. <i>Cancer Journal (Sudbury, Mass)</i> , <b>2012</b> , 18, 153-159	2.2	28
342	Cancer Immunotherapy. <b>2013</b> ,		1
341	Immune Co-signaling to Treat Cancer. <b>2013</b> , 211-280		1
340	Differing HLA types influence inhibitory receptor signalling in CMV-specific CD8+ T cells. <b>2013</b> , 74, 302-9		0
339	Tumor B7-H1 and B7-H3 expression in squamous cell carcinoma of the lung. <b>2013</b> , 14, 157-63		156
338	At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. <b>2013</b> , 94, 41-53		232
337	Endoplasmic reticulum stress response and inflammatory cytokines in type 2 diabetic nephropathy: role of indoleamine 2,3-dioxygenase and programmed death-1. <b>2013</b> , 94, 343-51		39

336	Counteracting immunosuppressive cofactor B7-H1 may enhance the effects of chemotherapy in cancer patients. <b>2013</b> , 5, 557-9	2
335	Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. <b>2013</b> , 19, 1021-34	381
334	Costimulatory molecules on immunogenic versus tolerogenic human dendritic cells. <b>2013</b> , 4, 82	136
333	Inflammation promotes oral squamous carcinoma immune evasion via induced programmed death ligand-1 surface expression. <b>2013</b> , 5, 1519-1526	13
332	Emerging Co-signaling Networks in T Cell Immune Regulation. <b>2013</b> , 13, 184-93	40
331	Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma. <b>2014</b> , 7, 567-73	172
330	Recent advances of immunotherapy in lung cancer: anti-programmed cell death-1/programmed death ligand-1 antibodies. <b>2014</b> , 3, 175-190	1
329	Harnessing the PD-1 pathway in renal cell carcinoma: current evidence and future directions. <b>2014</b> , 28, 513-26	7
328	The role of B7-H1 in gastric carcinoma: clinical significance and related mechanism. <b>2014</b> , 31, 268	19
327	Role of immunotherapy in the treatment of advanced non-small-cell lung cancer. <b>2014</b> , 10, 79-90	21
326	Targeting the PD1/PD-L1 axis in melanoma: biological rationale, clinical challenges and opportunities. <b>2014</b> , 89, 140-65	122
325	Checkpoint blocking antibodies in cancer immunotherapy. <b>2014</b> , 588, 368-76	184
324	The immunoinhibitory B7-H1 molecule as a potential target in cancer: killing many birds with one stone. <b>2014</b> , 7, 1-17	72
323	Immunotherapy: is a minor god yet in the pantheon of treatments for lung cancer?. <b>2014</b> , 14, 1173-87	23
322	Tumour-stroma crosstalk in the development of squamous cell carcinoma. <b>2014</b> , 53, 450-8	31
321	Inflammatory biomarkers and bladder cancer prognosis: a systematic review. <b>2014</b> , 66, 1078-91	66
320	The programmed death-1 immune-suppressive pathway: barrier to antitumor immunity. <b>2014</b> , 193, 3835-41	127
319	Tumor-Induced Immune Suppression. <b>2014</b> ,	1

318	The role of the PD-L1:PD-1 pathway in squamous cell carcinoma of the head and neck. <b>2014</b> , 50, 627-32	161
317	Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma. <b>2015</b> , 126, 2193-201	312
316	Emerging immunotherapies for bladder cancer. <b>2015</b> , 27, 191-200	21
315	Tumor associated PD-L1 expression pattern in microscopically tumor positive sentinel lymph nodes in patients with melanoma. <b>2015</b> , 13, 319	21
314	B7-H1/PD-1 blockade therapy in urological malignancies: current status and future prospects. <b>2015</b> , 101, 549-54	5
313	Nivolumab in the treatment of malignant melanoma: review of the literature. <b>2015</b> , 8, 2045-51	15
312	Immunotherapy for bladder cancer. <b>2015</b> , 7, 65-79	118
311	New developments in the management of advanced melanoma - role of pembrolizumab. <b>2015</b> , 8, 2535-43	13
310	New and promising strategies in the management of bladder cancer. <b>2015</b> , 105-12	14
309	Evolving immunotherapy strategies in urothelial cancer. <b>2015</b> , e284-90	3
308	Costimulation in Lymphomas and Cancers. <b>2015</b> , 185-254	4
307	PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma. <b>2015</b> , 89, 181-8	195
306	[Recent advances in bladder urothelial carcinogenesis]. <b>2015</b> , 102, 1020-35	3
305	Modification of sPD1 with CRT induces potent anti-tumor immune responses in vitro and in vivo. <b>2015</b> , 76, 57-64	1
304	Developments in T Cell Based Cancer Immunotherapies. <i>Cancer Drug Discovery and Development</i> , <b>2015</b> ,	0.3
303	The prognostic significance of PD-L1 in bladder cancer. <b>2015</b> , 33, 3075-84	77
302	Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma. <b>2015</b> , 26, 812-817	202
301	Evolving Concepts: Immunity in Oncology from Targets to Treatments. <b>2015</b> , 2015, 847383	20

300	Words of wisdom. Re: Surgical outcomes in the management of isolated nodal recurrences: a multicenter, international retrospective cohort. <b>2015</b> , 67, 974-5	2
299	Words of wisdom. Re: MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. <b>2015</b> , 67, 975	4
298	Inflammation and Cancer: What Can We Therapeutically Expect from Checkpoint Inhibitors?. <b>2015</b> , 16, 59	13
297	Second-line therapies in metastatic urothelial carcinoma. <b>2015</b> , 29, 341-59, x	4
296	Assessment of tumoral PD-L1 expression and intratumoral CD8+ T cells in urothelial carcinoma. <b>2015</b> , 85, 703.e1-6	88
295	Immune checkpoint protein inhibition for cancer: preclinical justification for CTLA-4 and PD-1 blockade and new combinations. <b>2015</b> , 42, 363-77	83
294	Diffuse high intensity PD-L1 staining in thymic epithelial tumors. <b>2015</b> , 10, 500-8	99
293	A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G. <b>2015</b> , 68, 267-79	144
292	Immunologic checkpoints blockade in renal cell, prostate, and urothelial malignancies. <b>2015</b> , 42, 495-505	36
291	Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized controlled trial. <b>2015</b> , 21, 1071-7	173
290	Anti-PD-1 and PD-L1 therapy for bladder cancer: what is on the horizon?. <b>2015</b> , 11, 2299-306	18
289	Dexamethasone enhances programmed cell death 1 (PD-1) expression during T cell activation: an insight into the optimum application of glucocorticoids in anti-cancer therapy. <b>2015</b> , 16, 39	73
288	Could PD-L1 prove to be an effective therapeutic target for bladder cancer?. <b>2015</b> , 7, 1-2	10
287	The biological complexity of urothelial carcinoma: Insights into carcinogenesis, targets and biomarkers of response to therapeutic approaches. <b>2015</b> , 35, 125-32	18
286	The PD-1/PD-L1 pathway: biological background and clinical relevance of an emerging treatment target in immunotherapy. <b>2015</b> , 19, 201-11	66
285	Nonmuscle invasive bladder cancer: a primer on immunotherapy. <b>2016</b> , 13, 194-205	14
284	Immunotherapy in urothelial carcinoma: fade or future standard?. <b>2016</b> , 5, 662-667	2
283	Regulation of cytotoxic T-cell responses by p53 in cancer. <i>Translational Cancer Research</i> , <b>2016</b> , 5, 692-697.3	26

282	The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation. <b>2016</b> , 7, 550		282
281	The Role of PD-L1 Expression and Intratumoral Lymphocytes in Response to Perioperative Chemotherapy for Urothelial Carcinoma. <b>2016</b> , 2, 425-432		18
280	PD-L1 expression in human cancers and its association with clinical outcomes. <b>2016</b> , 9, 5023-39		370
279	Epstein-Barr Virus-Associated Gastric Carcinoma and Specific Features of the Accompanying Immune Response. <b>2016</b> , 16, 1-7		41
278	Inhibiting Immune Checkpoints for the Treatment of Bladder Cancer. <b>2016</b> , 2, 15-25		21
277	The State of Immune Checkpoint Inhibition in Urothelial Carcinoma: Current Evidence and Future Areas of Exploration. <i>Cancer Journal (Sudbury, Mass)</i> , <b>2016</b> , 22, 96-100	2.2	4
276	Immunotherapy advances in uro-genital malignancies. <b>2016</b> , 105, 52-64		16
275	The current status of checkpoint inhibitors in metastatic bladder cancer. <b>2016</b> , 33, 629-35		9
274	Clinicopathologic and Prognostic Implications of Programmed Death Ligand 1 Expression in Thymoma. <b>2016</b> , 101, 1361-9		47
273	Urothelial Cancer: Inflammatory Mediators and Implications for Immunotherapy. <b>2016</b> , 30, 263-73		19
272	Relationship between expression of PD-L1 and PD-L2 on esophageal squamous cell carcinoma and the antitumor effects of CD8+ T cells. <b>2016</b> , 35, 699-708		48
271	Novel immunotherapeutic approaches to the treatment of urothelial carcinoma. <i>Therapeutic Advances in Urology</i> , <b>2016</b> , 8, 203-14	3.2	8
270	Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors. <b>2016</b> , 8, 583-600		52
269	Novel immunotherapy approaches for metastatic urothelial and renal cell carcinoma. <b>2016</b> , 3, 268-277		3
268	The role of antagonists of the PD-1:PD-L1/PD-L2 axis in head and neck cancer treatment. <b>2016</b> , 61, 152-8		40
267	The immune system and cancer evasion strategies: therapeutic concepts. <b>2016</b> , 279, 541-62		146
266	Cancer Immunotherapy by Checkpoint Blockade. <b>2016</b> , 561-580		
265	Emerging role of checkpoint inhibition in localized bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2016</b> , 34, 548-555	2.8	14

264	Emerging role of immunotherapy in urothelial carcinoma-Future directions and novel therapies. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2016</b> , 34, 566-576	2.8	5
263	Programmed cell death-1 pathway inhibitors in genitourinary malignancies: specific side-effects and their management. <b>2016</b> , 26, 548-55		7
262	Pharmacogenomics: Biomarker-Directed Therapy for Bladder Cancer. <b>2016</b> , 43, 77-86		8
261	Future directions in bladder cancer immunotherapy: towards adaptive immunity. <b>2016</b> , 8, 351-65		13
260	Basics of PD-1 in self-tolerance, infection, and cancer immunity. <b>2016</b> , 21, 448-55		50
259	The PD-1/PD-L1 axis in the pathogenesis of urothelial bladder cancer and evaluating its potential as a therapeutic target. <b>2016</b> , 12, 595-600		8
258	Chemotherapy for Muscle-Invasive Bladder Cancer. <b>2016</b> , 17, 6		8
257	Immunotherapy of Cancer. <b>2016</b> ,		2
256	Anti-PD-1 and Anti-PD-L1 mAbs. <b>2016</b> , 283-294		1
255	Systemic Immunotherapy of Non-Muscle Invasive Mouse Bladder Cancer with Avelumab, an Anti-PD-L1 Immune Checkpoint Inhibitor. <b>2016</b> , 4, 452-62		62
254	Expression of PDL1 (B7-H1) Before and After Neoadjuvant Chemotherapy in Urothelial Carcinoma. <b>2016</b> , 1, 265-268		31
253	New Strategies in Bladder Cancer: A Second Coming for Immunotherapy. <b>2016</b> , 22, 793-801		43
252	The Immune Checkpoint Regulator PD-L1 Is Highly Expressed in Aggressive Primary Prostate Cancer. <b>2016</b> , 22, 1969-77		128
251	Immune checkpoint inhibitors: a new frontier in bladder cancer. <b>2016</b> , 34, 49-55		11
250	Programmed Death-ligand 1 Expression in Upper Tract Urothelial Carcinoma. <b>2017</b> , 3, 502-509		18
249	Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study. <b>2017</b> , 18, 212-220		246
248	[Immunotherapy in uropathology]. <b>2017</b> , 37, 90-100		
247	A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now. <b>2017</b> , 54, 58-67		231

246	Prognostic significance of PD-L1 expression on tumor cells and tumor-infiltrating mononuclear cells in upper tract urothelial carcinoma. <b>2017</b> , 34, 94		36
245	Programmed Death Ligand-1 (PD-L1) Expression in the Programmed Death Receptor-1 (PD-1)/PD-L1 Blockade: A Key Player Against Various Cancers. <b>2017</b> , 141, 851-861		64
244	Prognostic significance of PD-L1 in solid tumor: An updated meta-analysis. <b>2017</b> , 96, e6369		113
243	Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications. <b>2017</b> , 198, 817-823		21
242	Atezolizumab: A PD-L1-Blocking Antibody for Bladder Cancer. <b>2017</b> , 23, 1886-1890		104
241	Immunotherapy: The Wave of the Future in Bladder Cancer?. <b>2017</b> , 15, S3-S17		6
240	Cancer immunotherapies targeting the PD-1 signaling pathway. <b>2017</b> , 24, 26		332
239	Contemporary update on neoadjuvant therapy for bladder cancer. <b>2017</b> , 14, 348-358		18
238	Correlation between messenger RNA expression and protein expression of immune checkpoint-associated molecules in bladder urothelial carcinoma: A retrospective study. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2017</b> , 35, 257-263	2.8	26
237	Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors. <b>2017</b> , 35, 207-216		53
236	Pharmacokinetic drug evaluation of atezolizumab for the treatment of locally advanced or metastatic urothelial carcinoma. <b>2017</b> , 13, 225-232		13
235	An aptamer for recognizing the transmembrane protein PDL-1 (programmed death-ligand 1), and its application to fluorometric single cell detection of human ovarian carcinoma cells. <b>2017</b> , 184, 4029-4035		28
234	Expressions of programmed death (PD)-1 and PD-1 ligand (PD-L1) in cervical intraepithelial neoplasia and cervical squamous cell carcinomas are of prognostic value and associated with human papillomavirus status. <b>2017</b> , 43, 1602-1612		48
233	Role of PD-1 in Immunity and Diseases. <b>2017</b> , 410, 75-97		85
232	Tumor programmed cell death ligand 1 expression correlates with nodal metastasis in patients with cutaneous squamous cell carcinoma of the head and neck. <b>2017</b> , 77, 527-533		35
231	PD-L1/PD-1 Pathway Blockade Reverses Dysfunction of Circulating CEA-Specific T Cells in Pancreatic Cancer Patients. <b>2017</b> , 23, 6178-6189		6
230	Immunohistochemical investigations on the expression of programmed cell death ligand 1, human leukocyte antigens G and E, and granzyme B in intraoral mucoepidermoid carcinoma. <b>2017</b> , 83, 55-62		15
229	PD-L1 and PD-1 expression correlate with prognosis in extrahepatic cholangiocarcinoma. <b>2017</b> , 14, 250-256		28

228	mRNA Expression levels of genes involved in antitumor immunity: Identification of a 3-gene signature associated with prognosis of muscle-invasive bladder cancer. <b>2017</b> , 6, e1358330		12
227	Emerging Concepts Targeting Immune Checkpoints in Cancer and Autoimmunity. <b>2017</b> ,		0
226	Landmarks in the treatment of muscle-invasive bladder cancer. <b>2017</b> , 14, 565-574		65
225	PD-L1 and immune escape: insights from melanoma and other lineage-unrelated malignancies. <b>2017</b> , 66, 13-33		34
224	Prognostic Value of PD-1 and PD-L1 Expression in Patients with High Grade Upper Tract Urothelial Carcinoma. <b>2017</b> , 198, 1253-1262		41
223	Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: A systematic review and meta-analysis of randomized controlled trials. <b>2017</b> , 96, e7325		65
222	A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2017</b> , 35, 14-20	2.8	45
221	PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas. <b>2017</b> , 14, 203-220		250
220	Oral Squamous Carcinoma Cells Express B7-H1 and B7-DC Receptors in Vivo. <b>2017</b> , 23, 99-110		6
219	Prognostic role of PD-L1 in malignant solid tumors: a meta-analysis. <b>2017</b> , 32, e68-e74		47
218	Vascular endothelial growth factor A amplification in colorectal cancer is associated with reduced M1 and M2 macrophages and diminished PD-1-expressing lymphocytes. <i>PLoS ONE</i> , <b>2017</b> , 12, e0175563	3.7	12
217	In vitro and in vivo antiviral activity of an anti-programmed death-ligand 1 (PD-L1) rat-bovine chimeric antibody against bovine leukemia virus infection. <i>PLoS ONE</i> , <b>2017</b> , 12, e0174916	3.7	23
216	Nonmuscle-invasive bladder cancer: what's changing and what has changed. <b>2017</b> , 84, 1-8		7
215	PD-L1 expression in bladder cancer and metastasis and its influence on oncologic outcome after cystectomy. <i>Oncotarget</i> , <b>2017</b> , 8, 66849-66864	3.3	38
214	Positive PD-L1 Expression Predicts Worse Outcome in Cutaneous Angiosarcoma. <b>2017</b> , 3, 360-369		25
213	Current markers and their value in the era of immuno-oncology. <b>2017</b> , 6, 1111-1116		5
212	Durvalumab in urothelial cancers. <b>2018</b> , 18, 311-318		6
211	Association between programmed cell death ligand-1 expression and extracranial metastasis in intracranial solitary fibrous tumor/hemangiopericytoma. <b>2018</b> , 139, 251-259		12

210	Restoration of Peripheral Intermediate and Classical Monocytes Expressing HLA-DR in Patients With Lung Adenocarcinoma After Platinum-Based Chemotherapy. <b>2018</b> , 17, 1533033818764720	2
209	Association of PD-L1 Expression with Tumor-Infiltrating Immune Cells and Mutation Burden in High-Grade Neuroendocrine Carcinoma of the Lung. <b>2018</b> , 13, 636-648	54
208	Immunotherapy with Checkpoint Blockade in the Treatment of Urothelial Carcinoma. <b>2018</b> , 199, 1129-1142	28
207	BCG and Anti-PDL-1 Ab in Bladder Cancers. <b>2018</b> , 357-369	
206	mRNA Vaccine with Antigen-Specific Checkpoint Blockade Induces an Enhanced Immune Response against Established Melanoma. <b>2018</b> , 26, 420-434	79
205	Diagnostic, Prognostic, and Predictive Biomarkers on Bladder Tissue and Blood. <b>2018</b> , 117-136	
204	Precision Molecular Pathology of Bladder Cancer. <b>2018</b> ,	
203	PD-1/PD-L1 and immune-related gene expression pattern in pediatric malignant brain tumors: clinical correlation with survival data in Korean population. <b>2018</b> , 139, 281-291	13
202	The emerging role of immunotherapy in advanced urothelial cancers. <b>2018</b> , 30, 172-180	5
201	PD-1 and cancer: molecular mechanisms and polymorphisms. <b>2018</b> , 70, 73-86	62
200	Current and Future Applications of Novel Immunotherapies in Urological Oncology: A Critical Review of the Literature. <b>2018</b> , 4, 442-454	6
199	Combination therapy strategies for improving PD-1 blockade efficacy: a new era in cancer immunotherapy. <b>2018</b> , 283, 110-120	104
198	Atezolizumab in urothelial bladder carcinoma. <b>2018</b> , 14, 331-341	5
197	Implications of the tumor immune microenvironment for staging and therapeutics. <b>2018</b> , 31, 214-234	182
196	Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. <b>2018</b> , 19, 51-64	362
195	Peptide Blocking of PD-1/PD-L1 Interaction for Cancer Immunotherapy. <b>2018</b> , 6, 178-188	78
194	Anti-PD-L1/TGFB2 (M7824) fusion protein induces immunogenic modulation of human urothelial carcinoma cell lines, rendering them more susceptible to immune-mediated recognition and lysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2018</b> , 36, 93.e1-93.e11	2.8 23
193	The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers. <b>2018</b> , 19, 120-129	48

192	High PDL1 mRNA expression predicts better survival of stage pT1 non-muscle-invasive bladder cancer (NMIBC) patients. <i>Cancer Immunology, Immunotherapy</i> , <b>2018</b> , 67, 403-412	7.4	39
191	Soluble PD-1 ligands regulate T-cell function in Waldenstrom macroglobulinemia. <b>2018</b> , 2, 1985-1997		27
190	Emerging Role of Immune Checkpoint Blockade in Pancreatic Cancer. <b>2018</b> , 19,		51
189	Synergistic Antitumor Effect on Bladder Cancer by Rational Combination of Programmed Cell Death 1 Blockade and CRISPR-Cas9-Mediated Long Non-Coding RNA Urothelial Carcinoma Associated 1 Knockout. <b>2018</b> , 29, 1352-1363		19
188	Immune checkpoint inhibitors as a real hope in advanced urothelial carcinoma. <b>2018</b> , 4, FSO341		6
187	PD-1 and PD-L1 are more highly expressed in high-grade bladder cancer than in low-grade cases: PD-L1 might function as a mediator of stage progression in bladder cancer. <b>2018</b> , 18, 97		24
186	[Prognostic value of PD-1/PD-L1 expression in upper tract urothelial carcinoma]. <b>2018</b> , 28, 900-905		
185	The intracellular signalosome of PD-L1 in cancer cells. <b>2018</b> , 3, 26		108
184	PD-1/PD-L1 pathway blockade works as an effective and practical therapy for cancer immunotherapy. <b>2018</b> , 15, 116-123		31
183	On the Road to Immunotherapy-Prospects for Treating Head and Neck Cancers With Checkpoint Inhibitor Antibodies. <b>2018</b> , 9, 2182		10
182	[Immunotherapy for locally advanced and metastasized bladder cancer]. <b>2018</b> , 57, 1334-1341		1
181	Genitourinary Cancers. <b>2018</b> ,		
180	Current Role of Checkpoint Inhibitors in Urologic Cancers. <b>2018</b> , 175, 241-258		5
179	Personalized Medicine. <b>2018</b> , 659-673		
178	Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations. <b>2018</b> , 37, 4639-4661		133
177	PD-L1 Expression and CD8 T Cell Infiltration Predict a Favorable Prognosis in Advanced Gastric Cancer. <b>2018</b> , 2018, 4180517		36
176	Endocrine, Sexual Function, and Infertility Side Effects of Immune Checkpoint Inhibitor Therapy for Genitourinary Cancers. <b>2018</b> , 19, 68		6
175	PD-L1 expression in tumor cells and the immunologic milieu of bladder carcinomas: a pathologic review of 165 cases. <b>2018</b> , 81, 184-191		12

174	Characterization of dermatitis after PD-1/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: A retrospective case-control study. <b>2018</b> , 79, 1047-1052		69
173	Evaluation of costimulatory molecules in dogs with B cell high grade lymphoma. <i>PLoS ONE</i> , <b>2018</b> , 13, e0201222	3.7	9
172	The prognostic value of PD-L1 expression in upper tract urothelial carcinoma varies according to platelet count. <b>2018</b> , 7, 4330-4338		16
171	PD-L1 Expression is Increased in Metastasizing Squamous Cell Carcinomas and Their Metastases. <b>2018</b> , 40, 647-654		28
170	PD-L1 expression in malignant salivary gland tumors. <b>2018</b> , 18, 156		28
169	PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse. <b>2018</b> , 11, 16		68
168	Approved checkpoint inhibitors in bladder cancer: which drug should be used when?. <b>2018</b> , 10, 1758835918788310		10
167	Quantification and prognostic value of programmed cell death ligand-1 expression in dogs with diffuse large B-cell lymphoma. <b>2018</b> , 79, 643-649		5
166	Targeting PD-1 in cancer: Biological insights with a focus on breast cancer. <b>2019</b> , 142, 35-43		13
165	Molecular and histopathology directed therapy for advanced bladder cancer. <b>2019</b> , 16, 465-483		73
164	Cisplatin contributes to programmed death-ligand 1 expression in bladder cancer through ERK1/2-AP-1 signaling pathway. <b>2019</b> , 39,		24
163	Prognostic and Clinicopathological Significance of PD-L1 in Patients With Bladder Cancer: A Meta-Analysis. <b>2019</b> , 10, 962		16
162	Programmed death ligand-1/programmed death-1 inhibition therapy and programmed death ligand-1 expression in urothelial bladder carcinoma. <b>2019</b> , 5, 170-177		2
161	Impact of Tumor and Immunological Heterogeneity on the Anti-Cancer Immune Response. <i>Cancers</i> , <b>2019</b> , 11,	6.6	22
160	The multifaceted immune regulation of bladder cancer. <b>2019</b> , 16, 613-630		58
159	Clinicopathological and prognostic value of PD-L1 in urothelial carcinoma: a meta-analysis. <i>Cancer Management and Research</i> , <b>2019</b> , 11, 4171-4184	3.6	19
158	PD-L1 expression on stromal tumor-infiltrating lymphocytes is a favorable prognostic factor in ovarian serous carcinoma. <b>2019</b> , 12, 56		15
157	The Novel Combination of Nitroxoline and PD-1 Blockade, Exerts a Potent Antitumor Effect in a Mouse Model of Prostate Cancer. <b>2019</b> , 15, 919-928		15

156	Organ preservation in bladder cancer: an opportunity for truly personalized treatment. <b>2019</b> , 16, 511-522	22
155	PD-L1 expression and clinical outcomes in patients with advanced urothelial carcinoma treated with checkpoint inhibitors: A meta-analysis. <b>2019</b> , 76, 51-56	22
154	Differential expressions of PD-1, PD-L1 and PD-L2 between primary and metastatic sites in renal cell carcinoma. <b>2019</b> , 19, 360	37
153	Tumor immune microenvironment in non-muscle-invasive urothelial carcinoma of the bladder. <b>2019</b> , 89, 24-32	9
152	Expression and prognostic utility of PD-L1 in patients with squamous cell carcinoma of the bladder. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2019</b> , 37, 478-484	2.8 7
151	Tolerability and efficacy of durvalumab in Japanese patients with advanced solid tumors. <b>2019</b> , 110, 1715-1723	9
150	The Inhibitory T Cell Receptors PD1 and 2B4 Are Differentially Regulated on CD4 and CD8 T Cells in a Mouse Model of Non-alcoholic Steatohepatitis. <b>2019</b> , 10, 244	1
149	PD-L1 Expression Reveals Significant Association With Squamous Differentiation in Upper Tract Urothelial Carcinoma. <b>2019</b> , 151, 561-573	9
148	Immunomodulators targeting the PD-1/PD-L1 protein-protein interaction: From antibodies to small molecules. <b>2019</b> , 39, 265-301	85
147	Product review: avelumab, an anti-PD-L1 antibody. <b>2019</b> , 15, 891-908	26
146	Intravesical BCG: where do we stand? Past, present and future. <b>2019</b> , 12, 425-435	1
145	Expression of immunoregulatory molecules PD-L1 and PD-1 in oral cancer and precancerous lesions: A cohort study of Japanese patients. <b>2019</b> , 47, 33-40	15
144	CD5+ diffuse large B-cell lymphoma, NOS: clinical characteristics and outcomes in rituximab era. <b>2020</b> , 61, 328-336	2
143	The evolving role of PD-L1 testing in patients with metastatic urothelial carcinoma. <b>2020</b> , 82, 101925	33
142	Tumor immune microenvironment is associated with the growth of intracranial germinomas. <b>2020</b> , 146, 139-146	2
141	Prognostic significance of pre- and post-treatment PD-L1 expression in patients with primary high-grade non-muscle-invasive bladder cancer treated with BCG immunotherapy. <b>2020</b> , 38, 2537-2545	8
140	Clinicopathological correlation of PD-L1 and TET1 expression with tumor-infiltrating lymphocytes in non-small cell lung cancer. <b>2020</b> , 216, 153188	1
139	Uncoupling Therapeutic Efficacy from Immune-Related Adverse Events in Immune Checkpoint Blockade. <b>2020</b> , 23, 101580	10

138	Expression status of PD-L1 and B7-H3 in mesothelioma. <b>2020</b> , 70, 999-1008		6
137	Increased PD-L1 expression in high-grade bladder cancer with squamous cell differentiation in Bulgarian and French patients. <b>2020</b> , 49, 151640		1
136	Pretreatment CT-Based Radiomics Signature as a Potential Imaging Biomarker for Predicting the Expression of PD-L1 and CD8+TILs in ESCC. <b>2020</b> , 13, 12003-12013		6
135	PD-L1 Expression and CD8+ Tumor-infiltrating Lymphocytes in Different Types of Tubo-ovarian Carcinoma and Their Prognostic Value in High-grade Serous Carcinoma. <b>2020</b> , 44, 1050-1060		12
134	Increased programmed death ligand (PD-L1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4) expression is associated with metastasis and poor prognosis in malignant canine mammary gland tumours. <b>2020</b> , 230, 110142		4
133	Focus on Biochemical and Clinical Predictors of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma: Where Do We Stand?. <b>2020</b> , 21,		11
132	Cancer immunotherapy harnessing T cells and programmed death-1. <b>2020</b> , 298, 237-253		4
131	Immune-related signature predicts the prognosis and immunotherapy benefit in bladder cancer. <b>2020</b> , 9, 7729-7741		13
130	Novel anticancer therapy in BCG unresponsive non-muscle-invasive bladder cancer. <b>2020</b> , 20, 965-983		5
129	PD-L1 and IDO1 expression and tumor-infiltrating lymphocytes in osteosarcoma patients: comparative study of primary and metastatic lesions. <b>2020</b> , 146, 2607-2620		11
128	Evaluation of PD-L1 expression on circulating tumor cells (CTCs) in patients with advanced urothelial carcinoma (UC). <b>2020</b> , 9, 1738798		14
127	Relapse-Free Survival and PD-L1 Expression in First High- and Low-Grade Relapsed Luminal, Basal and Double-Negative P53-Mutant Non-Muscular Invasive Bladder Cancer Depending on Previous Chemo- and Immunotherapy. <i>Cancers</i> , <b>2020</b> , 12,	6.6	4
126	Epigenetic modulation combined with PD-1/PD-L1 blockade enhances immunotherapy based on MAGE-A11 antigen-specific CD8+T cells against esophageal carcinoma. <b>2020</b> , 41, 894-903		6
125	An Avidity-Based PD-L1 Antagonist Using Nanoparticle-Antibody Conjugates for Enhanced Immunotherapy. <b>2020</b> , 20, 4901-4909		28
124	Clinical relevance and prognostic significance of PD-1/PD-Ls in non-metastatic bladder cancer: A role for PD-L2. <b>2020</b> , 124, 35-41		2
123	KEYNOTE-676: Phase III study of BCG and pembrolizumab for persistent/recurrent high-risk NMIBC. <b>2020</b> , 16, 507-516		25
122	PD-L1 Expression in Glioblastoma, the Clinical and Prognostic Significance: A Systematic Literature Review and Meta-Analysis. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 1015	5.3	23
121	Predictive and Prognostic Role of PD-L1 in Urothelial Carcinoma Patients with Anti-PD-1/PD-L1 Therapy: A Systematic Review and Meta-Analysis. <b>2020</b> , 2020, 8375348		1

120	Association of cancer progression with elevated expression of programmed cell death protein 1 ligand 1 by upper tract urothelial carcinoma and increased tumor-infiltrating lymphocyte density. <i>Cancer Immunology, Immunotherapy</i> , <b>2020</b> , 69, 689-702	7.4	7
119	Bladder cancer genomics. <b>2020</b> , 87, 49-56		8
118	MicroRNA-155-5p suppresses PD-L1 expression in lung adenocarcinoma. <b>2020</b> , 10, 1065-1071		3
117	Immunotherapy. <i>Advances in Experimental Medicine and Biology</i> , <b>2020</b> ,	3.6	1
116	Neoadjuvant immune checkpoint inhibitors in cancer, current state of the art. <b>2021</b> , 157, 103172		2
115	Future Strategies Involving Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma. <b>2020</b> , 22, 7		3
114	Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance. <b>2021</b> , 16, 223-249		151
113	PD-L1 expression in tumor-infiltrating lymphocytes (TILs) as an independent predictor of prognosis in patients with pN0 bladder cancer undergoing radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2021</b> , 39, 195.e15-195.e23	2.8	0
112	Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer. <i>Cancers</i> , <b>2021</b> , 13,	6.6	51
111	Identification and Immunocorrelation of Prognosis-Related Genes Associated With Development of Muscle-Invasive Bladder Cancer. <i>Frontiers in Molecular Biosciences</i> , <b>2020</b> , 7, 598599	5.6	2
110	Bladder Cancer. <b>2021</b> ,		0
109	Bladder Cancer Tissue-Based Biomarkers. <b>2021</b> , 2, 53-71		
108	PD-L1 Testing for Urothelial Carcinoma: Interchangeability, Reliability and Future Perspectives. <i>Current Drug Targets</i> , <b>2021</b> , 22, 162-170	3	5
107	Identification of a ten-long noncoding RNA signature for predicting the survival and immune status of patients with bladder urothelial carcinoma based on the GEO database: a superior machine learning model. <b>2021</b> , 13, 6957-6981		2
106	Oncolytic Virotherapy: The Cancer Cell Side. <i>Cancers</i> , <b>2021</b> , 13,	6.6	1
105	Epstein-Barr Virus LMP1 Induces Soluble PD-L1 in Nasopharyngeal Carcinoma. <b>2021</b> , 9,		4
104	Immune Checkpoint Inhibitors in Urothelial Carcinoma: Recommendations for Practical Approaches to PD-L1 and Other Potential Predictive Biomarker Testing. <i>Cancers</i> , <b>2021</b> , 13,	6.6	7
103	Prognostic value of PD-L1 combined positive score in patients with upper tract urothelial carcinoma. <i>Cancer Immunology, Immunotherapy</i> , <b>2021</b> , 70, 2981-2990	7.4	2

102	Pembrolizumab-induced myasthenia gravis-like disorder, ocular myositis, and hepatitis: a case report. <b>2021</b> , 15, 244		2
101	Design of PD-1-decorated nanocages targeting tumor-draining lymph node for promoting T cell activation. <b>2021</b> , 333, 328-338		3
100	High Serum PD-L1 Levels Are Associated with Poor Survival in Urothelial Cancer Patients Treated with Chemotherapy and Immune Checkpoint Inhibitor Therapy. <i>Cancers</i> , <b>2021</b> , 13,	6.6	5
99	Advances in the management of urothelial carcinoma: is immunotherapy the answer?. <b>2021</b> , 22, 1743-1759		1
98	The Efficacy of Intra-Arterial Plus Intravesical Chemotherapy Intravesical Chemotherapy Alone After Bladder-Sparing Surgery in High-Risk Bladder Cancer: A Systematic Review and Meta-Analysis of Comparative Study. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 651657	5.3	1
97	Treating Bladder Cancer: Engineering of Current and Next Generation Antibody-, Fusion Protein-, mRNA-, Cell- and Viral-Based Therapeutics. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 672262	5.3	4
96	Current Therapy for Metastatic Urothelial Carcinoma. <b>2021</b> , 35, 469-493		0
95	Tumor Immune Microenvironment Components and Checkpoint Molecules in Anaplastic Variant of Diffuse Large B-Cell Lymphoma. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 638154	5.3	1
94	Detection of PD-L1 in the urine of patients with urothelial carcinoma of the bladder. <i>Scientific Reports</i> , <b>2021</b> , 11, 14244	4.9	3
93	High PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor in urothelial carcinoma. <b>2021</b> , 17, 2893-2905		0
92	Programmed cell death ligand-1 expression and survival in a cohort of patients with non-small cell lung cancer receiving first-line through third-line therapy in Denmark. <b>2021</b> , 73, 101976		1
91	Perioperative pembrolizumab therapy in muscle-invasive bladder cancer: Phase III KEYNOTE-866 and KEYNOTE-905/EV-303. <b>2021</b> , 17, 3137-3150		8
90	Immune Checkpoint Inhibitors in Urothelial Bladder Cancer: State of the Art and Future Perspectives. <i>Cancers</i> , <b>2021</b> , 13,	6.6	8
89	The Potential of Tissue-Resident Memory T Cells for Adoptive Immunotherapy against Cancer. <i>Cells</i> , <b>2021</b> , 10,	7.9	2
88	Tumor-Associated Macrophages in Bladder Cancer: Biological Role, Impact on Therapeutic Response and Perspectives for Immunotherapy. <i>Cancers</i> , <b>2021</b> , 13,	6.6	4
87	Long non-coding RNAs as new players in bladder cancer: Lessons from pre-clinical and clinical studies. <i>Life Sciences</i> , <b>2021</b> , 288, 119948	6.8	10
86	Novel Insights into the Antagonistic Effects of Losartan against Angiotensin II/AGTR1 Signaling in Glioblastoma Cells. <i>Cancers</i> , <b>2021</b> , 13,	6.6	1
85	PD-L1 expression in bladder cancer: Which scoring algorithm in what tissue?. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2021</b> , 39, 734.e1-734.e10	2.8	1

84	Intermediate- and high-risk nonmuscle invasive bladder cancer: Where do we stand?. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2021</b> , 39, 631-641	2.8	3
83	Neoadjuvant immunotherapy for muscle invasive urothelial bladder carcinoma: will it change current standards?. <i>Therapeutic Advances in Urology</i> , <b>2021</b> , 13, 17562872211029779	3.2	2
82	Proteomics and cancer epidemiology. <i>Methods in Molecular Biology</i> , <b>2009</b> , 471, 197-215	1.4	9
81	Current Landscape of Immunotherapy in Genitourinary Malignancies. <i>Advances in Experimental Medicine and Biology</i> , <b>2020</b> , 1244, 107-147	3.6	2
80	Nivolumab. <b>2016</b> , 297-317		1
79	Mechanisms of Immune Evasion by Cancer. <b>2016</b> , 199-232		2
78	Spatiotemporal Changes in Checkpoint Molecule Expression. <i>Advances in Experimental Medicine and Biology</i> , <b>2020</b> , 1248, 167-200	3.6	3
77	Immune checkpoint inhibitors for the management of advanced non-small-cell lung carcinoma: a meta-analysis. <i>Anti-Cancer Drugs</i> , <b>2020</b> , 31, 637-645	2.4	4
76	Expression of B7 Homolog 1 (B7H1) Is Associated with Clinicopathologic Features in Urothelial Bladder Cancer. <i>Medical Science Monitor</i> , <b>2018</b> , 24, 7303-7308	3.2	3
75	Tumor infiltrating PD1-positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomas. <i>PLoS ONE</i> , <b>2013</b> , 8, e82870	3.7	206
74	Upregulation of Programmed Death-1 and Its Ligand in Cardiac Injury Models: Interaction with GADD153. <i>PLoS ONE</i> , <b>2015</b> , 10, e0124059	3.7	52
73	PD-L1 and Survival in Solid Tumors: A Meta-Analysis. <i>PLoS ONE</i> , <b>2015</b> , 10, e0131403	3.7	235
72	CD8+/FOXP3+ ratio and PD-L1 expression associated with survival in pT3N0M0 stage esophageal squamous cell cancer. <i>Oncotarget</i> , <b>2016</b> , 7, 71455-71465	3.3	34
71	Programmed cell death-ligand 1 expression predicts survival in patients with gastric carcinoma with microsatellite instability. <i>Oncotarget</i> , <b>2017</b> , 8, 13320-13328	3.3	50
70	Prognostic value of PD -L1 expression in patients with primary solid tumors. <i>Oncotarget</i> , <b>2018</b> , 9, 5058-5072	3.2	35
69	Enhanced expression of PD-L1 in non-muscle-invasive bladder cancer after treatment with Bacillus Calmette-Guerin. <i>Oncotarget</i> , <b>2018</b> , 9, 34066-34078	3.3	27
68	Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells. <i>Oncotarget</i> , <b>2016</b> , 7, 33350-62	3.3	45
67	Status of Programmed Death Ligand 1 (PD-L1) by Immunohistochemistry and Scoring Algorithms. <i>Current Drug Targets</i> , <b>2020</b> , 21, 1286-1292	3	4

66	PD1/PD-L1 Axis in Uro-oncology. <i>Current Drug Targets</i> , <b>2020</b> , 21, 1293-1300	3	3
65	Level of circulating PD-L1 expression in patients with advanced gastric cancer and its clinical implications. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , <b>2014</b> , 26, 104-11	3.8	80
64	New therapies in nonmuscle invasive bladder cancer treatment. <i>Indian Journal of Urology</i> , <b>2018</b> , 34, 11-10.8	10.8	23
63	Mechanism of T cell exhaustion in a chronic environment. <i>BMB Reports</i> , <b>2011</b> , 44, 217-31	5.5	40
62	Anti-PD-1 and Anti-B7-H1/PD-L1 Monoclonal Antibodies. <b>2012</b> , 291-306		
61	Miscellaneous Approaches and Considerations: TLR Agonists and Other Inflammatory Agents, Anti-Chemokine Agents, Infectious Agents, Tumor Stroma Targeting, Age and Sex Effects, and Miscellaneous Small Molecules. <b>2013</b> , 399-424		
60	Overcoming Immune Suppression: Therapeutic Strategies Targeting T-Cell Function in Cancer. <b>2014</b> , 435-462		
59	T Cell Modulation: Anti-PD-1 Antibodies for the Treatment of Cancer. <i>Cancer Drug Discovery and Development</i> , <b>2015</b> , 231-244	0.3	
58	Adjuvant Treatment: Old and New Immunotherapy in Non-Muscle-Invasive Bladder Cancer. <b>2018</b> , 43-47		
57	Nivolumab (Opdivo). <b>2019</b> , 255-283		1
56	The Role of TGF- $\beta$ and PD-L1 in the Invasion and Development of Bladder Cancer. <i>Advances in Clinical Medicine</i> , <b>2020</b> , 10, 1917-1925	0	
55	Immunosuppression Induced by Glutamine Deprivation Occurs Activating PD-L1 Transcription in Bladder Cancer. <i>Frontiers in Molecular Biosciences</i> , <b>2021</b> , 8, 687305	5.6	0
54	Targeting immune checkpoints: releasing the restraints on anti-tumor immunity for patients with melanoma. <i>Cancer Journal (Sudbury, Mass)</i> , <b>2012</b> , 18, 153-9	2.2	23
53	Expression of programmed death-1 ligand (PD-L1) in tumor-infiltrating lymphocytes is associated with favorable spinal chordoma prognosis. <i>American Journal of Translational Research (discontinued)</i> , <b>2016</b> , 8, 3274-87	3	33
52	Expression of PD-L1 in mononuclear cells, multinucleated cells, and foam cells in tenosynovial giant cell tumors. <i>International Journal of Clinical and Experimental Pathology</i> , <b>2019</b> , 12, 876-884	1.4	
51	Programmed death ligand 1 expression in bladder rhabdomyosarcoma and its association with clinicopathological features. <i>International Journal of Clinical and Experimental Pathology</i> , <b>2017</b> , 10, 10565-10570	1.4	10570
50	Intravesical Therapy for Non-muscle Invasive Bladder Cancer-Current and Future Options in the Age of Bacillus Calmette-Guerin Shortage. <i>Reviews in Urology</i> , <b>2019</b> , 21, 145-153	1	8
49	PD-1/PD-L1 pathway: current researches in cancer. <i>American Journal of Cancer Research</i> , <b>2020</b> , 10, 727-742	742	156

48	Clinical retrospective study on the expression of the PD-L1 molecule in sporadic colorectal cancer and its correlation with K-ras gene mutations in Chinese patients. <i>American Journal of Translational Research (discontinued)</i> , <b>2021</b> , 13, 6142-6155	3	1
47	What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 2: Clinic-Pathologic Correlations. <i>Cells</i> , <b>2021</b> , 10,	7.9	8
46	The Prognostic Significance of PD1 and PDL1 Gene Expression in Lung Cancer: A Meta-Analysis. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 759497	5.3	0
45	Soluble PD-L1 in Serum and Urine in Urinary Bladder Cancer Patients. <i>Cancers</i> , <b>2021</b> , 13,	6.6	1
44	Landscape of Immunotherapy in Genitourinary Malignancies.. <i>Advances in Experimental Medicine and Biology</i> , <b>2021</b> , 1342, 143-192	3.6	0
43	Neoadjuvant chemotherapy for upper tract urothelial carcinoma.. <i>Translational Cancer Research</i> , <b>2020</b> , 9, 6576-6582	0.3	0
42	DNA damage response inhibitor and anti-PD-L1 therapy for prostate cancer: Development of predictive biomarkers. <i>Engineering</i> , <b>2022</b> ,	9.7	
41	Clinical Case Debate: Neoadjuvant Checkpoint Inhibition Versus Standard Chemotherapy. <b>2022</b> , 13-25		
40	CD274 (PD-L1) Methylation is an Independent Predictor for Bladder Cancer Patients'Survival.. <i>Cancer Investigation</i> , <b>2022</b> , 1-6	2.1	2
39	Immune-Checkpoint Inhibitors in Advanced Bladder Cancer: Seize the Day.. <i>Biomedicines</i> , <b>2022</b> , 10,	4.8	0
38	Immune Contexture and Differentiation Features Predict Outcome in Bladder Cancer.. <i>European Urology Oncology</i> , <b>2022</b> ,	6.7	0
37	The Evolution of Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma.. <i>Cancers</i> , <b>2022</b> , 14,	6.6	0
36	Improving the role of immune checkpoint inhibitors in the management of advanced urothelial carcinoma, where do we stand?. <i>Translational Oncology</i> , <b>2022</b> , 19, 101387	4.9	1
35	Expression and Prognostic Implication of PD-L1 in Patients with Urothelial Carcinoma with Variant Histology (Squamous Differentiation or Micropapillary) Undergoing Radical Cystectomy.. <i>Biomedicines</i> , <b>2022</b> , 10,	4.8	
34	Data_Sheet_1.pdf. <b>2019</b> ,		
33	Immune Microenvironment Terms Signature Robustly Predicts the Prognosis and Immunotherapy Response in Bladder Cancer Based on Large Population Cohorts. <i>Frontiers in Genetics</i> , <b>2022</b> , 13,	4.5	
32	Tumor-immune microenvironment revealed by Imaging Mass Cytometry in a metastatic sarcomatoid urothelial carcinoma with a prolonged response to pembrolizumab.. <b>2022</b> , 8,		0
31	Emerging treatment landscape of non-muscle invasive bladder cancer. <i>Expert Opinion on Biological Therapy</i> , 1-18	5.4	0

30 Immunologische Biomarkerforschung in der Urologie III Beispiel Urothelkarzinom.

29	Treatment Options for Metastatic Urothelial Carcinoma After First-Line Chemotherapy. <i>Cancer Management and Research</i> , Volume 14, 1945-1960	3.6	○
28	Comprehensive analysis of the PD-L1 and immune infiltrates of N6-methyladenosine related long non-coding RNAs in bladder cancer. <i>Scientific Reports</i> , <b>2022</b> , 12,	4.9	
27	Sequence-specific 1H, 13C and 15N backbone NMR assignments for the N-terminal IgV-like domain (D1) and full extracellular region (D1D2) of PD-L1. <i>Biomolecular NMR Assignments</i> ,	0.7	1
26	Impact of Programmed Death-ligand 1 Expression on Oncological Outcomes in Patients with Muscle-invasive Bladder Cancer Treated with Radiation-based Therapy. <i>European Urology Open Science</i> , <b>2022</b> , 43, 14-21	0.9	
25	A Protein Kinase D Inhibitor Suppresses AKT on T cells and Antagonizes Cancer Immunotherapy by Anti-PD-1. <i>International Immunology</i> ,	4.9	○
24	Prognostic values of the immune microenvironment-related non-coding RNA IGF2BP2-AS1 in bladder cancer. <i>Cell Cycle</i> , 1-17	4.7	
23	Targeting the androgen receptor to enhance NK cell killing efficacy in bladder cancer by modulating ADAR2/circ_0001005/PD-L1 signaling.		1
22	A comprehensive pan-cancer analysis of the expression characteristics, prognostic value, and immune characteristics of TOP1MT. 13,		
21	Detailed bladder cancer immunoprofiling reveals new clues for immunotherapeutic strategies. <b>2022</b> , 11,		○
20	Interferon gamma expression and mortality in unselected cohorts of urothelial bladder cancer patients. <b>2022</b> , 17, e0271339		○
19	Potential of the therapeutic effect of intravesical BCG through synthetic and biogenic selenium nanoparticles in a nitrosamine-induced bladder cancer mouse model. <b>2022</b> , 6, 100061		○
18	Loss of Major Histocompatibility Complex Class I, CD8+ Tumor-infiltrating Lymphocytes, and PD-L1 Expression in Ovarian Clear Cell Carcinoma. Publish Ahead of Print,		○
17	Immune Checkpoint Inhibitors in Urothelial Carcinoma (Literature Review). <b>2022</b> , 12, 205-216		○
16	BCG downregulates PD1 and PD-L1 expression in bladder cancer cells co-cultivated with peripheral blood mononuclear cells. <b>2022</b> , 5,		○
15	Correlation between PD-L1 expression of the tumour cells and lymphocytes infiltration in the invasive front of urothelial carcinoma. jclinpath-2021-207795		○
14	Landscape of the intratumoral microenvironment in bladder cancer: Implications for prognosis and immunotherapy. <b>2023</b> , 21, 74-85		1
13	Urine PD-L1 is a tumor tissue candidate substitute and is associated with poor survival in muscle-invasive bladder cancer patients. <b>2023</b> , 114, 109535		○

- 12 Role of lymphocytes, macrophages and immune receptors in suppression of tumor immunity. **2022**, ○
- 11 Enhanced anti-tumor immunity of vaccine combined with anti-PD-1 antibody in a murine bladder cancer model. 64, ○
- 10 Mechanisms of Resistance and Strategies to Combat Resistance in PD-(L)1 Blockade. **2022**, 2, 671-691 ○
- 9 In silico mapping of the dynamic interactions and structure-activity relationship of flavonoid compounds against the immune checkpoint programmed-cell death 1 pathway. 2, ○
- 8 The gene signature of tertiary lymphoid structures within ovarian cancer predicts the prognosis and immunotherapy benefit. 13, ○
- 7 Tumor immunology. **2023**, 245-452 ○
- 6 Modeling tumour heterogeneity of PD-L1 expression in tumour progression and adaptive therapy. **2023**, 86, ○
- 5 Genitourinary cancers immune biomarkers: a comprehensive overview. **2023**, 389-409 ○
- 4 Immunotherapy with immune checkpoint inhibitors and predictive biomarkers in malignant mesothelioma: Work still in progress. 14, ○
- 3 Immune Checkpoint Inhibitors in Urological Cancers. **2023**, 1-25 ○
- 2 PD-L1, a Master Regulator of Immunity 2.0. **2023**, 24, 4385 ○
- 1 Biomarker expression and survival in patients with non-small cell lung cancer receiving adjuvant chemotherapy in Denmark. **2023**, 18, e0284037 ○